Although some other studies on the combination of BRAF or MEK inhibitors and CDK 4/6 inhibitors demonstrated promising antitumor activity in melanoma, this was accompanied by significant toxicity, limiting the applicability of this strategy [96]. Here, BRAF is linked to melanoma.